AERI being acquired - up 30%+ on the day

Shares of Aerie Pharmaceuticals (AERI) are trading 35% higher at a price of $15.105 at the time of this writing. The Health Care sector is having a generally somewhat bearish day, this hasn't really affected the stock's share price, as it outperforming other names in the space.

The stock is moving on news that Alcon is acquiring the company for 770M.

Aerie Pharmaceuticals has been trading between a 52-week high of $17.21 and a 52-week low of $4.81. The stock has a market cap of $746 Million.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

As you can imagine, the internet had a few things to say about the price move. Here's a few choice comments from the Reddit Traderverse™:

MistaMastaLoKey777 - -3 upvotes - source
Don't sleep on AERI today degens